{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:51:29Z","timestamp":1790484689810,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA101642"],"award-info":[{"award-number":["CA101642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00262-019-02402-z","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T11:56:44Z","timestamp":1570708604000},"page":"1747-1757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy"],"prefix":"10.1007","volume":"68","author":[{"given":"Donastas","family":"Sakellariou-Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Andr\u00e9e","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantale","family":"Bernatchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"issue":"1","key":"2402_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD (2018) Jemal A (2018) cancer statistics. CA Cancer J Clin 68(1):7\u201330. \nhttps:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2402_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/CCO.0000000000000111","volume":"26","author":"E Zsiros","year":"2014","unstructured":"Zsiros E, Tanyi J, Balint K, Kandalaft LE (2014) Immunotherapy for ovarian cancer: recent advances and perspectives. Curr Opin Oncol 26(5):492\u2013500. \nhttps:\/\/doi.org\/10.1097\/CCO.0000000000000111","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"2402_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10):719\u2013725. \nhttps:\/\/doi.org\/10.1038\/nrc3144","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2402_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1053\/j.seminoncol.2008.12.002","volume":"36","author":"MM Leitao","year":"2009","unstructured":"Leitao MM, Chi DS (2009) Surgical management of recurrent ovarian cancer. Semin Oncol 36(2):106\u2013111. \nhttps:\/\/doi.org\/10.1053\/j.seminoncol.2008.12.002","journal-title":"Semin Oncol"},{"issue":"4","key":"2402_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF02888158","volume":"11","author":"M Ding","year":"1991","unstructured":"Ding M, Mei-jiao G (1991) Immune effect of tumor-infiltrating lymphocytes and its relation to the survival rate of patients with ovarian malignancies. J Tongji Med Univ 11(4):5","journal-title":"J Tongji Med Univ"},{"issue":"3","key":"2402_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203\u2013213. \nhttps:\/\/doi.org\/10.1056\/NEJMoa020177","journal-title":"N Engl J Med"},{"issue":"51","key":"2402_CR7","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538\u201318543. \nhttps:\/\/doi.org\/10.1073\/pnas.0509182102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2402_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","volume":"58","author":"N Leffers","year":"2009","unstructured":"Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58(3):449\u2013459. \nhttps:\/\/doi.org\/10.1007\/s00262-008-0583-5","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2402_CR9","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","volume":"18","author":"JS Nielsen","year":"2012","unstructured":"Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27\u2212 memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281\u20133292. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0234","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2402_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bjc.2013.32","volume":"108","author":"Y Ino","year":"2013","unstructured":"Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N (2013) Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 108(4):914\u2013923. \nhttps:\/\/doi.org\/10.1038\/bjc.2013.32","journal-title":"Br J Cancer"},{"issue":"1","key":"2402_CR11","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","volume":"28","author":"A Fukunaga","year":"2004","unstructured":"Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H (2004) CD8+ Tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1):e26\u2013e31. \nhttps:\/\/doi.org\/10.1097\/00006676-200401000-00023","journal-title":"Pancreas"},{"issue":"8","key":"2402_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"10","key":"2402_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020\u20131030. \nhttps:\/\/doi.org\/10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"issue":"1","key":"2402_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"2","key":"2402_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122\u2013133. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1302369","journal-title":"N Engl J Med"},{"issue":"10105","key":"2402_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(17)31601-x","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet 390(10105):1853\u20131862. \nhttps:\/\/doi.org\/10.1016\/s0140-6736(17)31601-x","journal-title":"The Lancet"},{"issue":"2","key":"2402_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"3","key":"2402_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17(3):299\u2013308. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(15)00544-6","journal-title":"Lancet Oncol"},{"issue":"19","key":"2402_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"8","key":"2402_CR20","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105(8):3005\u20133010. \nhttps:\/\/doi.org\/10.1073\/pnas.0712237105","journal-title":"Proc Natl Acad Sci USA"},{"issue":"34","key":"2402_CR21","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33(34):4015\u20134022. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.62.3397","journal-title":"J Clin Oncol"},{"issue":"26","key":"2402_CR22","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"issue":"13","key":"2402_CR23","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550\u20134557. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2402_CR24","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16(9):2646\u20132655. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0041","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2402_CR25","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","volume":"18","author":"LG Radvanyi","year":"2012","unstructured":"Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758\u20136770. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1177","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2402_CR26","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-17-3649","volume":"24","author":"MA Forget","year":"2018","unstructured":"Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C (2018) Prospective analysis of adoptive til therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416\u20134428. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3649","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2402_CR27","first-page":"1934","volume":"51","author":"Y Aoki","year":"1991","unstructured":"Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T (1991) Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian-cancer. Can Res 51(7):1934\u20131939","journal-title":"Can Res"},{"issue":"3","key":"2402_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00002371-199410000-00004","volume":"16","author":"RS Freedman","year":"1994","unstructured":"Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S et al (1994) Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 16(3):198\u2013210","journal-title":"J Immunother Emphasis Tumor Immunol"},{"issue":"1","key":"2402_CR29","first-page":"190","volume":"54","author":"H Ikarashi","year":"1994","unstructured":"Ikarashi H, Fujita K, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K (1994) Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res 54(1):190\u2013196","journal-title":"Cancer Res"},{"issue":"5","key":"2402_CR30","first-page":"501","volume":"1","author":"K Fujita","year":"1995","unstructured":"Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K (1995) Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1(5):501\u2013507","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2402_CR31","first-page":"2268","volume":"6","author":"RS Freedman","year":"2000","unstructured":"Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD (2000) Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6(6):2268\u20132278","journal-title":"Clin Cancer Res"},{"issue":"32","key":"2402_CR32","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233\u20135239. \nhttps:\/\/doi.org\/10.1200\/JCO.2008.16.5449","journal-title":"J Clin Oncol"},{"issue":"3","key":"2402_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1158\/1078-0432.CCR-14-1934","volume":"21","author":"JA Chacon","year":"2015","unstructured":"Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi L (2015) Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res 21(3):611\u2013621. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1934","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2402_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/2326-6066.CIR-16-0364","volume":"5","author":"M Harao","year":"2017","unstructured":"Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM (2017) 4-1BB-Enhanced Expansion of CD8+ TIL from triple-negative breast cancer unveils mutation-specific CD8+ T cells. Cancer Immunol Res 5(6):439\u2013445. \nhttps:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0364","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"2402_CR35","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.1158\/1078-0432.CCR-17-0831","volume":"23","author":"D Sakellariou-Thompson","year":"2017","unstructured":"Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C (2017) 4-1BB agonist focuses CD8(+) Tumor-infiltrating T-Cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer. Clin Cancer Res 23(23):7263\u20137275. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0831","journal-title":"Clin Cancer Res"},{"key":"2402_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000230","author":"RJ Tavera","year":"2018","unstructured":"Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C (2018) Utilizing T-cell activation signals 1, 2, and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma. J Immunother. \nhttps:\/\/doi.org\/10.1097\/CJI.0000000000000230","journal-title":"J Immunother"},{"issue":"9","key":"2402_CR37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/CJI.0000000000000056","volume":"37","author":"MA Forget","year":"2014","unstructured":"Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E, Marincola FM, Hwu P, Cooper LJ, Radvanyi LG (2014) Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 37(9):448\u2013460. \nhttps:\/\/doi.org\/10.1097\/CJI.0000000000000056","journal-title":"J Immunother"},{"issue":"11","key":"2402_CR38","doi-asserted-by":"publisher","first-page":"e0141864","DOI":"10.1371\/journal.pone.0141864","volume":"10","author":"BI Moon","year":"2015","unstructured":"Moon BI, Kim TH, Seoh JY (2015) Functional modulation of regulatory T Cells by IL-2. PLoS One 10(11):e0141864. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0141864","journal-title":"PLoS One"},{"issue":"8","key":"2402_CR39","doi-asserted-by":"publisher","first-page":"e1014246","DOI":"10.1080\/2162402X.2015.1014246","volume":"4","author":"CL Haymaker","year":"2015","unstructured":"Haymaker CL, Wu RC, Ritthipichai K, Bernatchez C, Forget MA, Chen JQ, Liu H, Wang E, Marincola F, Hwu P, Radvanyi LG (2015) BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. Oncoimmunology 4(8):e1014246. \nhttps:\/\/doi.org\/10.1080\/2162402X.2015.1014246","journal-title":"Oncoimmunology"},{"issue":"20","key":"2402_CR40","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1158\/1078-0432.CCR-16-1217","volume":"23","author":"K Ritthipichai","year":"2017","unstructured":"Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C (2017) Multifaceted role of BTLA in the control of CD8(+) T-cell fate after antigen encounter. Clin Cancer Res 23(20):6151\u20136164. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1217","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2402_CR41","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.4049\/jimmunol.178.7.4112","volume":"178","author":"P Romero","year":"2007","unstructured":"Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, Rufer N (2007) Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 178(7):4112\u20134119. \nhttps:\/\/doi.org\/10.4049\/jimmunol.178.7.4112","journal-title":"J Immunol"},{"issue":"4","key":"2402_CR42","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.coi.2007.06.004","volume":"19","author":"H Shin","year":"2007","unstructured":"Shin H, Wherry EJ (2007) CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 19(4):408\u2013415. \nhttps:\/\/doi.org\/10.1016\/j.coi.2007.06.004","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2402_CR43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm.4278","volume":"23","author":"SQ Crome","year":"2017","unstructured":"Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, Milea A, Sowamber R, Katz SR, Bernardini MQ, Clarke BA, Shaw PA, Lang PA, Berman HK, Pugh TJ, Lanier LL, Ohashi PS (2017) A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat Med 23(3):368\u2013375. \nhttps:\/\/doi.org\/10.1038\/nm.4278","journal-title":"Nat Med"},{"issue":"2","key":"2402_CR44","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH (2014) Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 20(2):434\u2013444. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1877","journal-title":"Clin Cancer Res"},{"issue":"46","key":"2402_CR45","doi-asserted-by":"publisher","first-page":"75130","DOI":"10.18632\/oncotarget.12077","volume":"7","author":"FL Komdeur","year":"2016","unstructured":"Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N, Helfrich W, Samplonius DF, Bremer E, Wisman GB, Daemen T, Duiker EW, Hollema H, Nijman HW, de Bruyn M (2016) CD103\u2009+\u2009intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRalphabeta\u2009+\u2009CD8alphabeta\u2009+\u2009T cells that can be targeted for cancer immunotherapy. Oncotarget 7(46):75130\u201375144. \nhttps:\/\/doi.org\/10.18632\/oncotarget.12077","journal-title":"Oncotarget"},{"issue":"7","key":"2402_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.humimm.2008.05.001","volume":"69","author":"OD Solberg","year":"2008","unstructured":"Solberg OD, Mack SJ, Lancaster AK, Single RM, Tsai Y, Sanchez-Mazas A, Thomson G (2008) Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol 69(7):443\u2013464. \nhttps:\/\/doi.org\/10.1016\/j.humimm.2008.05.001","journal-title":"Hum Immunol"},{"issue":"17","key":"2402_CR47","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1158\/1078-0432.CCR-05-0596","volume":"11","author":"J Yokokawa","year":"2005","unstructured":"Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11(17):6342\u20136351. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0596","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2402_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00262-011-1100-9","volume":"61","author":"OE Rahma","year":"2012","unstructured":"Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN (2012) A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 61(3):373\u2013384. \nhttps:\/\/doi.org\/10.1007\/s00262-011-1100-9","journal-title":"Cancer Immunol Immunother"},{"key":"2402_CR49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0573","author":"DC Deniger","year":"2018","unstructured":"Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, Wunderlich JR, Danforth DN, Somerville RPT, Rosenberg SA (2018) T-cell responses to TP53 \u201chotspot\u201d mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0573","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2402_CR50","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","volume":"24","author":"NR Hardwick","year":"2018","unstructured":"Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M (2018) p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clin Cancer Res 24(6):1315\u20131325. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2709","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2402_CR51","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1117208109","volume":"109","author":"K Odunsi","year":"2012","unstructured":"Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jager E (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 109(15):5797\u20135802. \nhttps:\/\/doi.org\/10.1073\/pnas.1117208109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2402_CR52","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/hum.2014.006","volume":"25","author":"E Lanitis","year":"2014","unstructured":"Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr (2014) A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther 25(8):730\u2013739. \nhttps:\/\/doi.org\/10.1089\/hum.2014.006","journal-title":"Hum Gene Ther"},{"issue":"20 Pt 1","key":"2402_CR53","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106\u20136115. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1183","journal-title":"Clin Cancer Res"},{"issue":"7463","key":"2402_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van\u2019t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Australian Pancreatic Cancer Genome I, Consortium IBC, Consortium IM-S, PedBrain I, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415\u2013421. \nhttps:\/\/doi.org\/10.1038\/nature12477","journal-title":"Nature"},{"issue":"5","key":"2402_CR55","doi-asserted-by":"publisher","first-page":"e0155189","DOI":"10.1371\/journal.pone.0155189","volume":"11","author":"SD Martin","year":"2016","unstructured":"Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH (2016) Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One 11(5):e0155189. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0155189","journal-title":"PLoS One"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02402-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T23:10:34Z","timestamp":1602198634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02402-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02402-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the 1975 Helsinki declaration. Ethical approval and tissue from surgical resections used to expand TIL were both obtained under protocols (PA16-0912\u00a0and LAB02-188) approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study for their specimens and data to be used in research and for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"COV318 and COV362 were originally purchased from Sigma\u2013Aldrich (now Millipore-Sigma, St. Louis, MO) and SKOV3 from the American Type Culture Collection (ATCC, Manassas, VA). All OvCa cell lines were HLA-typed, STR fingerprinted, and confirmed mycoplasma-free at MDACC.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}